CA2974395C - Compounds and methods for preventing or treating sensory hair cell death - Google Patents

Compounds and methods for preventing or treating sensory hair cell death Download PDF

Info

Publication number
CA2974395C
CA2974395C CA2974395A CA2974395A CA2974395C CA 2974395 C CA2974395 C CA 2974395C CA 2974395 A CA2974395 A CA 2974395A CA 2974395 A CA2974395 A CA 2974395A CA 2974395 C CA2974395 C CA 2974395C
Authority
CA
Canada
Prior art keywords
compound
formula
another embodiment
c6alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2974395A
Other languages
English (en)
French (fr)
Other versions
CA2974395A1 (en
Inventor
Julian Simon
Graham Johnson
Edwin W. Rubel
David W. Raible
Mario D. GONZALEZ
Peter C. Meltzer
Weishi Miao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oricula Therapeutics LLC
University of Washington
Fred Hutchinson Cancer Center
Original Assignee
Oricula Therapeutics LLC
University of Washington
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oricula Therapeutics LLC, University of Washington, Fred Hutchinson Cancer Center filed Critical Oricula Therapeutics LLC
Publication of CA2974395A1 publication Critical patent/CA2974395A1/en
Application granted granted Critical
Publication of CA2974395C publication Critical patent/CA2974395C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2974395A 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death Active CA2974395C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113245P 2015-02-06 2015-02-06
US62/113,245 2015-02-06
PCT/US2016/016880 WO2016127123A2 (en) 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death

Publications (2)

Publication Number Publication Date
CA2974395A1 CA2974395A1 (en) 2016-08-11
CA2974395C true CA2974395C (en) 2023-08-22

Family

ID=56564889

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2974395A Active CA2974395C (en) 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death

Country Status (10)

Country Link
US (2) US9493482B2 (enExample)
EP (1) EP3253766B1 (enExample)
JP (1) JP6697808B2 (enExample)
KR (1) KR102557184B1 (enExample)
CN (1) CN107438613B (enExample)
AU (1) AU2016215023B2 (enExample)
CA (1) CA2974395C (enExample)
DK (1) DK3253766T3 (enExample)
ES (1) ES2760373T3 (enExample)
WO (1) WO2016127123A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127123A2 (en) 2015-02-06 2016-08-11 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
DK3675865T3 (da) 2017-09-01 2025-05-26 Univ Washington Krystallinske former af forbindelser til forebyggelse eller behandling af sensorisk hårcelledød
WO2020033322A1 (en) * 2018-08-06 2020-02-13 Fred Hutchinson Cancer Research Center Hearing loss-protective compounds and methods thereof
US20240350492A1 (en) 2020-07-10 2024-10-24 Ting Therapeutics Llc Methods for the Prevention and Treatment of Hearing Loss
KR102848315B1 (ko) * 2022-10-27 2025-08-20 고려대학교 산학협력단 암모늄 락테이트를 유효성분으로 포함하는 난청 예방 또는 치료용 약학 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES457780A1 (es) 1977-04-14 1978-08-16 Made Labor Sa Un procedimiento para la obtencion de 7,10-dimetil-5,9-imi- no-4,5,8,9 - tetrahidrocicloocta (b) tiofenos.
ES462993A1 (es) 1977-10-07 1978-06-01 Made Labor Sa Un procedimiento para la obtencion simultanea de 6,7,10-tri-metil-5,9-imino-4,5,8,9-tetrahidrocicloocta(b)furano y de alfa-2,4,5-trimetilfuro(2,3-f)morfano.
US4174396A (en) 1978-04-03 1979-11-13 Laboratories Made, S.A. 7,10-Dimethyl-5,9-imino-4,5,8,9-tetrahydro-cyclooct[b]thiophenes and a process for obtaining it
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
JPH0778017B2 (ja) 1985-12-28 1995-08-23 住友製薬株式会社 パルス的かつ持続放出性製剤
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
ES2149781T3 (es) 1991-11-22 2000-11-16 Procter & Gamble Pharma Composiciones de risedronato de liberacion retardada.
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
EP0665010B1 (en) 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
EP0827402A2 (en) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
WO2003002569A1 (en) 2001-06-29 2003-01-09 Novo Nordisk A/S Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48
CA2572750A1 (en) 2003-09-10 2005-03-17 Anil Koul Heterobicyclic compounds as pharmaceutically active agents
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
US20050267182A1 (en) 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
US20060188445A1 (en) 2005-02-22 2006-08-24 Fred Hutchinson Cancer Research Center Assay for compounds that protect against sensory hair cell death and compounds identified by same
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US20110158911A1 (en) 2009-07-01 2011-06-30 Trustees Of Dartmouth College Methods for Screening for Antibiotic Compounds
DK2900674T3 (en) * 2012-09-28 2017-07-03 Univ Washington Through Its Center For Commercialization RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
WO2016127123A2 (en) 2015-02-06 2016-08-11 University Of Washington Compounds and methods for preventing or treating sensory hair cell death

Also Published As

Publication number Publication date
KR20180003530A (ko) 2018-01-09
WO2016127123A3 (en) 2016-10-27
AU2016215023B2 (en) 2019-12-19
US20160229869A1 (en) 2016-08-11
JP6697808B2 (ja) 2020-05-27
CN107438613B (zh) 2020-08-25
US10399994B2 (en) 2019-09-03
HK1246791A1 (en) 2018-09-14
DK3253766T3 (da) 2019-12-09
US20180022756A1 (en) 2018-01-25
KR102557184B1 (ko) 2023-07-18
EP3253766A2 (en) 2017-12-13
CA2974395A1 (en) 2016-08-11
CN107438613A (zh) 2017-12-05
ES2760373T3 (es) 2020-05-13
EP3253766A4 (en) 2018-07-25
US9493482B2 (en) 2016-11-15
EP3253766B1 (en) 2019-09-04
JP2018504411A (ja) 2018-02-15
AU2016215023A1 (en) 2017-09-07
WO2016127123A2 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
CA2974395C (en) Compounds and methods for preventing or treating sensory hair cell death
US9902738B2 (en) Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
CA2968061C (en) Prodrugs of phenolic trpv1 agonists
JP2024531170A (ja) 真性糖尿病に対するメニン－ｍｌｌ相互作用の共有結合性阻害剤
US12145913B2 (en) Inhibition of Olig2 activity
HK1246791B (en) Compounds and methods for preventing or treating sensory hair cell death
WO2012058325A1 (en) Compounds and methods useful for treatment of diseases mediated by hif-1
CN118076357A (zh) 用于糖尿病的Mennin-MLL相互作用的共价抑制剂
WO2020033322A1 (en) Hearing loss-protective compounds and methods thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210115

EEER Examination request

Effective date: 20210115

EEER Examination request

Effective date: 20210115

EEER Examination request

Effective date: 20210115

EEER Examination request

Effective date: 20210115

EEER Examination request

Effective date: 20210115

EEER Examination request

Effective date: 20210115

EEER Examination request

Effective date: 20210115

EEER Examination request

Effective date: 20210115

EEER Examination request

Effective date: 20210115

EEER Examination request

Effective date: 20210115